Compare Eli Lilly And Co (LLY) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Mercadolibre Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Mercadolibre Inc trades at $1,889.85 (market cap $94.13B). The key difference: Eli Lilly And Co is far larger — about 11× Mercadolibre Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Mercadolibre Inc for 117 Days on average.
| LLY | MELI | |
|---|---|---|
Market Cap | $1.04T | $94.13B |
Volume | 3,064,878 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $2.36K |
52-Week Low | $799.57 | $1.55K |
Typical Hold Time | 93 Days | 117 Days |
Enterprise Value | $1.09T | $101.77B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
MercadoLibre (MELI) trades at $1,889.85, up 0.91% on the day, with a bullish technical signal and strong analyst support. Revenue grew to $28.89 billion in 2025, though net income margin dipped to 6.91%. The company is expanding its fintech ecosystem, with credit portfolio surging 75% to $16.4 billion in Q2 2026. Operating cash flow remains robust at $12.12 billion, supporting aggressive investment in logistics and market expansion across Latin America.
Outlook is positive given dominant market position and integrated e-commerce-fintech model, but valuation multiples like P/E of 50.51 suggest high growth expectations. Risks include macroeconomic pressures in key markets like Argentina and intense regional competition. Analyst consensus is strongly bullish with a $2,170 price target, indicating ~15% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
